Strategies for Primary Care Physicians to Modify Cardiorenal Risk and Provide Optimal Management for Patients with Type 2 Diabetes and Chronic Kidney Disease
Webinar/Online
Wednesday, September 25, 2024 at 7:30pm CT - 8:30pm CT
This event has ended.
Info
Topic
CKD
Credits Offered
This event offers
1.0 CME credit
to attendees.
Accreditation Info:
Accreditation Council for Continuing Medical Education (ACCME).
Additional Information
Join us for this great talk on a very relevant topic:
“Strategies for Primary Care Physicians to Modify Cardiorenal Risk and Provide Optimal Management for Patients with Type 2 Diabetes and Chronic Kidney Disease”
Learning objectives:
- Interpret guideline recommended criteria for prompt recognition and diagnosis of CKD in patients with T2D
- Assess the latest clinical evidence for therapeutic agents for the management of CKD in patients with T2D that provide cardiorenal protective benefits
- Choose strategies for selecting the right patient to minimize cardiovascular risks and CKD progression
Audience:
This activity is designed to meet the educational needs of primary care clinicians working with a multidisciplinary team of cardiologists, nephrologists, nurses, pharmacists, and other HCPs to ensure recognition of CKD risk in patients with T2D and novel strategies for modifying CKD risk and the risk of other chronic complications of T2D. The grand round is accredited for physicians 1.0 AMA PRA Category 1 Credit(s)™. RNs and APNs will be awarded 1.00 contact hour(s) of continuing nursing education.
A mandatory Pre and Post-CME survey will be needed for CME credit to be given.
Speakers
Professor of Medicine
Washington University School of Medicine
St. Louis, Missouri
Dr. McGill graduated from Michigan State University College of Human Medicine, then completed her internship, residency and was chief resident in internal medicine at William Beaumont Hospital in Royal Oak Michigan. After her fellowship in Endocrinology at Washington University, she joined the faculty in 1987. She has been an active clinical researcher in diabetes for over 25 years, and continues to test new therapies for diabetes and novel approaches to type 1 and type 2 diabetes. Dr. McGill has served on steering and safety committees for multi-centered clinical trials, including RENAAL, TREAT, FOCAL, KEEP, SUN and PERL studies in diabetic nephropathy; and currently serves on planning committees and data safety monitoring boards for a number of ongoing national and international clinical trials. She is a past member of the board of directors for the American Association of Clinical Endocrinologists, and the AACE Diabetes Scientific Committee that recently published updated guidelines for the care of persons with type 2 diabetes. Dr. McGill is the former director of the Fellowship in Endocrinology, Diabetes and Metabolism and has a busy practice at the Center for Advanced Medicine treating patients with diabetes, thyroid disease and other endocrine problems.